Skip to main content
. 2021 Oct 26;71(11):2300–2312. doi: 10.1136/gutjnl-2021-324646

Figure 6.

Figure 6

Impact of PD-L1 blockade on HBV core18-specific and pol455-specific CD8+ T cell responses. HBV-specific CD8+ T cell responses following in vitro stimulation with core18-specific or pol455-specific peptides in presence or absence of anti-PD-L1 antibody. (A) Patients with CHB with HBsAg <100 or ≥10 000 IU/mL and (B) patients with CHB with HBcrAg <3 or >3 Log U/mL. Statistical significance was tested by Wilcoxon test. ns, not significant; *p<0.05; **p<0.01. CHB, chronic hepatitis B; HBcrAg, hepatitis B core-related antigen; HBsAg, hepatitis B surface antigen; IFN, interferon; PD-L1, programmed cell death ligand 1; pol, polymerase; TNF, tumour necrosis factor.